Abliva

0,443

SEK

+0,11 %

Mindre end 1K følgere

ABLI

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Finansielt overblik og estimater

Ownership

+0,11%

-1,56%

+4,98%

+214,63%

+140,5%

+186,18%

+4,02%

-36,56%

-90,12%

Abliva is a pharmaceutical company focused on developing innovative treatments for neurological diseases. The company is researching new therapies that can improve the quality of life for patients with neurological conditions. The company operates globally with a primary presence in Europe and North America. Abliva was founded in 2018 and is headquartered in Lund, Sweden.

Markedsværdi

714,06 mio. SEK

Aktieomsætning

254,7 t SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Finanskalender

28.3

2025

Ekstraordinær generalforsamling '25

22.5

2025

Delårsrapport Q1'25

12.6

2025

Generalforsamling '25

Alle

Selskabspræsentationer

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Selskabsmeddelelse3.3.2025, 12.10

Delisting of the shares of Abliva: last day of trading 17 March 2025

Selskabsmeddelelse26.2.2025, 07.30

Notice of Extraordinary General Meeting in Abliva AB (publ)

Selskabsmeddelelse25.2.2025, 08.50

Abliva applies for delisting and will convene an extraordinary general meeting

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Selskabsmeddelelse21.2.2025, 07.30

Abliva AB Year-End Report January – December 2024

Pressemeddelelse10.2.2025, 09.43

BioStock: Pharming completes bid for Abliva

Selskabsmeddelelse15.12.2024, 19.00

Statement by the Board of Directors of Abliva regarding the public cash offer from Pharming

Pressemeddelelse9.12.2024, 07.32

Abliva Announces Publication of Results from Phase 1a/b Study of KL1333 in the Scientific Journal Brain

Pressemeddelelse4.12.2024, 10.34

BioStock: From mutation to solution - Abliva gains ground

Selskabsmeddelelse29.11.2024, 17.00

Abliva AB Interim Report January – September 2024

Pressemeddelelse4.11.2024, 10.00

Abliva will present at the BioStock Life Science Summit, November 21

Pressemeddelelse18.9.2024, 07.38

BioStock: Abliva leads the fight against mitochondrial disease

Pressemeddelelse16.9.2024, 06.30

Join Abliva for World Mitochondrial Disease Week 2024, September 16 – 22

Selskabsmeddelelse30.8.2024, 06.30

Amended number of shares and votes in Abliva AB (publ)

Pressemeddelelse26.8.2024, 06.46

BioStock: Abliva's CEO - We are the leading programme in mitochondrial disease

Selskabsmeddelelse22.8.2024, 06.30

Abliva AB Interim Report January – June 2024

Pressemeddelelse24.7.2024, 09.57

Abliva's CEO to BioStock: "One step closer to a marketed medicine"

Selskabsmeddelelse19.7.2024, 06.30

Positive interim analysis in Abliva's FALCON study triggers convertible loan conversion

Selskabsmeddelelse18.7.2024, 20.22

Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease

Selskabsmeddelelse31.5.2024, 06.30

Amended number of shares and votes in Abliva AB (publ)

Pressemeddelelse30.5.2024, 10.40

Abliva Announces Completion of 24 Weeks of Dosing in Wave 1 of the FALCON Study of KL1333 in Primary Mitochondrial Disease

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.